top of page


Onco-Summaries: Daily Oncology Updates at a Glance
10/09/2025 Greenwich LifeSciences' GLSI-100 received the FDA fast track designation for HER2+ve breast cancer ( Ref ) The US FDA granted...
Oncofocus Team
Sep 11, 20252 min read


Onco-Summaries: Daily Oncology Updates at a Glance
05/09/2025 CERo Therapeutics' CER-1236 received the FDA Fast Track Designation for AML ( Ref ) The US FDA granted the Fast Track...
Oncofocus Team
Sep 8, 20251 min read


Onco-Summaries: Daily Oncology Updates at a Glance
28/08/2025 TOLREMO Therapeutics' TT125-802 received two fast track designations from the US FDA for NSCLC ( Ref ) The US FDA granted two...
Oncofocus Team
Aug 29, 20252 min read


Onco-Summaries: Daily Oncology Updates at a Glance
26/08/2025 Genmab's Rina-S ADC received the Breakthrough Therapy Designation from the FDA for endometrial cancer ( Ref ) The US FDA...
Oncofocus Team
Aug 27, 20252 min read


Onco-Summaries: Daily Oncology Updates at a Glance
14/08/2025 Halda's HLD-0915 received the Fast Track Designation from the US FDA for mCRPC ( Ref ) The US FDA granted the Fast Track...
Oncofocus Team
Aug 18, 20251 min read


Onco-Summaries: Daily Oncology Updates at a Glance
29/07/2025 Calidi Biotherapeutics' CLD-201 received the US FDA Fast Track Designation for soft tissue sarcoma ( Ref ) The US FDA granted...
Oncofocus Team
Jul 30, 20251 min read


Onco-Summaries: Daily Oncology Updates at a Glance
28/07/2025 sNDA for Akeso and Summit's ivonescimab (PD-1 x VEGF bispecific antibody) + chemotherapy for sqNSCLC accepted by China's NMPA...
Oncofocus Team
Jul 28, 20253 min read


Onco-Summaries: Daily Oncology Updates at a Glance
24/07/2025 GenFleet Therapeutics and Verastem Oncology's VS-7375 received the Fast Track Designation from the US FDA for pancreatic...
Oncofocus Team
Jul 25, 20252 min read


Onco-Summaries: Daily Oncology Updates at a Glance
09/07/2025 Artera's ArteraAI Prostate received the Breakthrough Device designation from the US FDA ( Ref ) The US FDA granted the...
Oncofocus Team
Jul 10, 20251 min read


Onco-Summaries: Daily Oncology Updates at a Glance
29/04/2025 ALX Oncology’s Phase 2 ASPEN-03 & ASPEN-04 trials failed to meet the primary endpoint of ORR ( Ref 1 ) ALX Oncology hit with a...
Oncofocus Team
Apr 29, 20252 min read
bottom of page
.png)